Empagliflozin for kidney function in lupus nephritis
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have lupus nephritis confirmed by kidney biopsy, with active class III, IV, or mixed III/IV or III/V disease.
- Your kidney function (eGFR) is 30 or higher.
- Your urine protein level is very high (over 1000 mg per gram of creatinine).
- You do not have type 1 or type 2 diabetes, or atrial fibrillation.
- You have no severe liver problems or life expectancy less than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
This study tests a medication called an SGLT2 inhibitor (usually used for diabetes, but being studied for kidney disease) to see if it can reduce the amount of protein leaking into the urine in people with chronic kidney disease from lupus nephritis or ANCA-associated vasculitis, which may help protect the kidneys.
This trial tests a new treatment for people with lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and protect kidney function.
This trial tests if empagliflozin, a diabetes medicine that also helps the heart, can improve symptoms in children with heart failure. It may help kids with severe symptoms or high levels of a heart stress marker called BNP.
This trial tests whether SGLT2 inhibitors (a type of diabetes medicine) can help adults with primary nephrotic syndrome, a kidney disease that causes protein leakage and swelling. It aims to see if the drug can protect kidney function and reduce protein loss.
This early trial studies whether empagliflozin can improve ulcerative colitis symptoms and is safe for people with mild to moderate disease. If it works, it may reduce ongoing colon inflammation and help people feel better.
Hear when a new Lupus Nephritis (LN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.